Observational Study of Ultravist in Patients Requiring CECT (INDEX)

Bayer

Status: Completed

Conditions: Diagnostic Imaging

Treatments: Drug: Iopromide (Ultravist, BAY86-4877)

Study type: Observational

Funder types: Industry

Identifiers

NCT01415414

15515

UV1011CN (Other Identifier)

Details and patient eligibility

About

It is a prospective, non-interventional, multi-center study. The primary objective of this study is to evaluate the image quality of Ultravist in patients requiring contrast-enhanced CT considering the routine use in patient population's, region's indication.

Enrollment: 11,660 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients undergoing contrast enhanced CT Imaging with Ultravist (iopromide) in abdomen or pelvis.

Exclusion criteria

• There is no other exclusion criteria beyond the contraindications contained in the Summary of Product Characteristics

Trial design

11,660 participants in 1 patient group

Group 1

Treatment:

Drug: Iopromide (Ultravist, BAY86-4877)